Shilpa Medicare530549Pharmaceuticals
Shilpa Medicare gained 2% after one of its plants received a USFDA approval or acceptance letter for a key drug
By ScoutQuest · · 1 min read
- Stock move today
- 2 percent higher
Heard on business television between 15:37:28 - 15:40:28 IST.
- Stock ended the day 2% higher.
- Gain came after the company's plant received a USFDA approval or acceptance letter for a key drug.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Shilpa Medicare
Shilpa Medicare rose about 4.5% after its partner Unicycive Therapeutics received USFDA acceptance of a resubmitted NDA application for a chronic kidney disease drug
22 Oct 2026
Viewer asked about entering Shilpa Medicare after a 2.7% decline; analyst said wait for the fall to stabilize before buying
15 Oct 2026
Nimesh flagged possible buying by a large global sovereign fund in Shilpa Medicare at current levels
14 Oct 2026
Source: Live TV News Channel · 22 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.